跳至主要内容
临床试验/NCT03908528
NCT03908528已完成不适用

Role of Alpha-Lipoic Acid Against Chemotherapy Induced Toxicities in Breast Cancer Patients

Damanhour University1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2019年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
64
试验地点
1
主要终点
MDA

研究概览

简要总结

• Investigate the ability of alpha lipoic acid to counter act anthracycline associated cardiotoxicity and cumulative taxens-related PN in patients with breast cancer.

详细描述

Fifty breast cancer patients with stage from stage I to stage III will be involved in this study. Staging is done according to the American joint committee on cancer: TNM staging of breast cancer.

  • All participants will be recruited from Tanta Oncology Center. The study will be approved by Research Ethics Committee of Damanhour University. All participants will give their consent.
  • All 64 patients will be scheduled to receive 4 cycles of AC: cycled every 21 days followed by weekly cycle of taxol for 12 weeks.

Patients will be classified as follow:

  • Group one: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks plus placebo.
  • Group two: 32 patients will receive the same regimen as group 1 in addition to oral 600 mg alpha lipoic acid (ALA) once daily.

All patients will be submitted to:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • All patients age ≥ 18 and < 70 years old with confirmed stage from stage I to stage III.
  • No evidence of metastases at initial assessment.
  • Patients has to have a good performance status (ECOG 0-2) according to Eastern Cooperative Oncology Group (ECOG) score.
  • Adequate baseline hematologic values (absolute neutrophilic count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L, and hemoglobin level ≥ 10g/dL).
  • Patients with adequate liver function (serum creatinine < 1.5 mg/dL) and adequate renal function (serum creatinine < 1.5 mg/dL, creatinine clearance (CrCl) > 45 ml/min).
  • Either pre operative or post operative chemotherapy are allowed.

排除标准

  • Evidence of metastases at initial assessment.
  • Pregnancy or breast-feeding patients.
  • Prior exposure to neurotoxic chemotherapy was not allowed (no carboplatin, vincristine, vinblastine, paclitaxel, or docetaxol ) for 6 months prior study treatment.
  • Clinical evidence of serious cardiac illness (myocardial dysfunctional, angina pectoris requiring anti-angina medication, poorly controlled hypertension, and uncontrolled arrhythmias).
  • Patients with a reduced cardiac output with a left ventricular ejection fraction (LVEF) ejection fraction < 50%.
  • Patients who had evidence of pre-existing peripheral neuropathy resulting from another reason (diabetes).
  • Patients with a history of allergy to alpha-lipoic acid.
  • Concomitant use of multivitamins (vitamin E), opioids, anticonvulsants, tricyclic antidepressants, other neuropathic pain medication modifying agents (e.g., gabapentin, lamotrigine, carbamazepine, phenytoin, or tricyclic antidepressants) are not allowed

结局指标

主要结局

MDA

时间窗: six months

Malondialdehyde

Neurotoxicity assessment

时间窗: six months

Neurotensin level

Cardiotoxcity assessment

时间窗: six months

serum Brain Natriuretic Peptide (BNP) level

oxidative stress and inflammatory markers

时间窗: six months

TNF-alpha level

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Rehab Werida

Lecturer

Damanhour University

研究点 (1)

Loading locations...

相似试验